Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Durect starts Phase III Chronogesic study

DRRX started a 12-month 100-patient open-label

Read the full 65 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE